The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19

Ken Arimura,Etsuko Tagaya,Ken Kikuchi,Toshihiro Mitsuda,Fumiya Ebihara,Takumi Maruyama,Yukihiro Hamada,Kohei Unagami,Taichi Kanzawa,Haruki Sekiguchi,Ken Shimamoto,Hideki Ishida,Hiroto Egawa,Junji Tanaka,Masatoshi Kawana

Transplant Immunology（2023）

引用 0|浏览21

暂无评分

摘要

•Casirivimab/imdevimab was effective in TRs with mild-to-moderate COVID-19.•Casirivimab/imdevimab increased the neutralizing antibody in TRs with mild-to-moderate COVID-19.•This may help prevent the progression of mild-to-moderate COVID-19 in TRs.

查看译文

关键词

Casirivimab/imdevimab,TRs,SARS-CoV-2,COVID-19,Neutralizing antibody

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要